Clostridium perfringens CPB monoclonal antibody hybridoma cell strain and application thereof

By constructing the recombinant protein rCPBΔ and screening monoclonal antibody hybridoma cell lines, the problems of low antigen content and complex diagnostic methods of existing vaccines are solved, and efficient and safe antibody detection and vaccine replacement are achieved, which are suitable for prevention and control of a variety of animals and diagnosis.

CN118955663APending Publication Date: 2024-11-15CHINA INST OF VETERINARY DRUG CONTROL

Patent Information

Application Number
CN202411213122.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing Clostridium perfringen vaccine has low effective antigen content, resulting in poor immune effect, and the expression of recombinant CPB is low, making it difficult to effectively prevent the disease. The existing diagnostic methods have complicated operation, high cost or side effects. etc.

Method used

By selecting the hydrophilic region of natural CPB, the recombinant protein rCPBΔ was constructed, and monoclonal antibody hybridoma cell lines secreted against CPB were screened, and indirect ELISA detection method was established, and CPB antibody blocking ELISA detection method was provided, using non-toxic rCPBΔ as a package Monoclonal antibody screening is performed by antigen to simplify the toxin detection process.

Benefits of technology

It realizes safe and effective antibody detection, reduces the risk of side reactions of vaccines, simplifies operating procedures, improves the specificity and sensitivity of diagnosis, and provides an alternative to traditional vaccines, suitable for prevention and diagnosis of a variety of animals.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005020775910000011
    Figure HDA0005020775910000011
  • Figure HDA0005020775910000012
    Figure HDA0005020775910000012
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and relates to a clostridium perfringens CPB monoclonal antibody hybridoma cell strain and application thereof. On the basis of selecting natural CPB, a region with relatively strong hydrophilicity is intercepted, recombinant protein is constructed and expressed, an indirect ELISA detection method is established, a hybridoma cell strain secreting the monoclonal antibody resisting CPB is screened, and an antibody blocking ELISA method of CPB is established, so that an alternative method is provided for CPB antibody detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to a Clostridium perfringens CPB monoclonal antibody hybridoma cell strain and application thereof. Background Art

[0002] Clostridium perfringens (C. perfringens), also known as Clostridium perfringens, is a zoonosis pathogen that can secrete a variety of lethal exotoxins. It is widely distributed in nature (soil, sewage, feed, feces, etc.) and has a wide range of hosts, including cattle, pigs, sheep, chickens and humans (FU Y, ALENEZI T, SUN XL. Clostridium perfringens-induced necrotic diseases: an overview [J]. Immuno, 2022, 2 (2): 387-407.). Clostridium perfringens can secrete nearly 20 toxins, among which the most important pathogenic toxins are α, β, ε and τ toxins, enterotoxins (C. perfringens entero-toxin, CPE) and necrotic enteritis B-like toxin (NetB). In addition, CP can be divided into 7 serotypes according to the toxins it mainly produces, namely type A (α toxin), type B (α, β and ε toxins), type C (α and β toxins), type D (α and ε toxins), type E (α and τ toxins), type F (α toxin and CPE) and type G (α toxin and NetB) (Kiu R, Hall LJ. An update on the human and animal enteric pathogen Clostridium perfringens [J]. Emerg Microbes Infect, 2018, 7 (1): 1-15.). Due to the different hosts and main pathogenic toxins of each type of CP, the diseases they cause are also different. Type A is the most common type, mainly causing gas gangrene, food poisoning and necrotic enteritis in poultry; types B, C and G cause necrotic enteritis in sheep and ruminants; types D and E cause animal enterotoxemia; type F causes food poisoning and antibiotic-associated diarrhea in humans. Since the disease is mainly caused by lethal exotoxins, the onset of the disease is rapid, the course of the disease is short, and the mortality rate is extremely high. Once the disease occurs, it is often too late to treat and sudden death occurs. Therefore, vaccination is an effective method to prevent and control the disease. At present, the main vaccine to prevent infection with this bacteria is a natural toxoid vaccine prepared by inactivating the supernatant of Clostridium culture. However, the effective antigen content and immune effect of this type of vaccine are not ideal. Therefore, screening safe, effective, and pure antigens for the development of new Clostridium perfringens disease vaccines is of great significance for preventing infection with this bacteria.

[0003] CPB is a perforating toxin that affects the distribution of calcium ions in nerve cell membranes, thereby affecting the function of nerve tissue and disrupting normal nerve conduction. CPB is considered to be the main virulence factor of Clostridium perfringens type C and type B strains, and causes "sudden death syndrome" in almost all livestock, including sheep anthrax and necrotic enteritis and enterotoxemia in newborn animals such as pigs, lambs, and calves, seriously endangering the healthy development of animal husbandry (CHEN K, AHMED S, SHENG YJ, SUNCF, DENG CL, OJHA SC. Diagnostic accuracy of nucleic acid amplification-based assays for Clostridium perfringens-associated diseases: a systematic review and meta-analysis [J]. Journal of Clinical Microbiology, 2020, 58 (9): e00363-e00320.). The pathogenic mechanism of CPB is to bind to endothelial cells, oligomerize and form perforations, eventually leading to swelling and cell lysis, causing intestinal damage and / or toxins from the intestine to penetrate into the intestinal blood circulation, causing death. CPB is encoded by the cpb gene. The precursor protein contains a total of 336 amino acids, of which the 1st to 27th amino acids are removed during the secretion process, thus becoming an active mature toxin. Due to the characteristics of CPB being heat-resistant, highly sensitive to in vitro trypsin and pepsin, and easy to polymerize to form polymers, it is difficult to purify it from natural Clostridium perfringens culture. Therefore, obtaining recombinant CPB through exogenous expression is a good way, but existing studies have found that due to the hydrophobicity of the N-terminus of CPB, the expression level of exogenously expressed recombinant CPB is low.

[0004] At present, the prevention of the disease mainly relies on inactivated vaccines, but the antibody titer produced by them will decrease over time (CHEN K, AHMED S, SHENG YJ, SUN CF, DENG CL, OJHA SC. Diagnostic accuracy of nucleic acid amplification-based assays for Clostridium perfringens-associated diseases: a systematic review and meta-analysis [J]. Journal of Clinical Microbiology, 2020, 58 (9): e00363-e00320.). Therefore, it is very important to establish sensitive, specific, rapid and accurate diagnostic methods for disease diagnosis and antibody level monitoring. Methods for detecting C. perfringens include bacterial isolation and culture, molecular biology and serological testing. Bacterial isolation and culture have the disadvantages of being cumbersome and time-consuming; PCR or fluorescent quantitative PCR methods have the disadvantages of being expensive, requiring special equipment, and having high requirements for operators (CHEN K, AHMED S, SHENGYJ, SUNCF, DENG CL, OJHA SC. Diagnostic accuracy of nucleic acid amplification-based assays for Clostridium perfringens-associated diseases: a systematic review and meta-analysis [J]. Journal of Clinical Microbiology, 2020, 58 (9): e00363-e00320.), while the ELISA method has the advantages of high sensitivity, strong specificity, simple operation, and can monitor animal antibody levels. Traditional natural toxin inactivated vaccines are usually used for immunization prevention for animals such as cattle, sheep, and rabbits, but there is a lack of relevant toxin detection and treatment methods. Due to the complex antigen composition and low effective content of natural toxin inactivated vaccines, they are prone to cause side effects in animals, making them incapable of being used for prevention in animals such as dogs and pigs. Existing studies have shown that the preparation of monoclonal antibodies can provide a basis for the treatment and diagnosis of certain toxins. The key to the preparation of monoclonal antibodies is the immunogen and the coating antigen, but the preparation, purification and inactivation of natural toxins are complex and have high biosafety risks. Summary of the invention

[0005] The present invention selects natural CPB, intercepts the region with strong hydrophilicity, constructs the expression of recombinant protein, establishes an indirect ELISA detection method, screens a hybridoma cell line that secretes anti-CPB monoclonal antibodies, and establishes an antibody blocking ELISA method for CPB, thereby providing an alternative method for CPB antibody detection.

[0006] In a first aspect, the present invention provides a biological sequence encoding type C Clostridium perfringens CPB, wherein the biological sequence refers to the 30th to 306th amino acid region with higher hydrophilicity in the CPB sequence of type C Clostridium perfringens, and its amino acid sequence is shown in SEQ ID NO: 1.

[0007] In a second aspect, the present invention provides a recombinant protein, which is encoded by the biological sequence described in the first aspect: a recombinant protein secreted by a competent cell after a synthetic gene fragment encoded by the biological sequence described in the first aspect is constructed into a vector and transformed into a competent cell, and is named rCPB Δ .

[0008] Furthermore, the synthetic gene fragment includes codon optimization of the gene encoding type C Clostridium perfringens CPB and the addition of a tag protein.

[0009] Furthermore, the codon optimization refers to optimization according to the preferred codons of Escherichia coli.

[0010] Furthermore, the adding of the tag protein refers to adding a 6×His tag protein to the C-terminus of the tandem gene.

[0011] Furthermore, the vector is a prokaryotic expression vector, preferably a pET30a vector.

[0012] Furthermore, the competent cell is Escherichia coli, preferably Escherichia coli BL21 (DE3).

[0013] In a third aspect, the present invention provides a hybridoma cell strain that secretes anti-Clostridium perfringens CPB monoclonal antibodies, and the accession number of the hybridoma cell strain is: CGMCC NO.46025.

[0014] In a fourth aspect, the present invention provides a method for screening the hybridoma cell line according to the third aspect, the screening method comprising the following steps:

[0015] S1. Immunize mice, determine serum titer by ELISA, and use spleen cells of mice with the highest titer for cell fusion;

[0016] S2. Take the mouse spleen cells screened in S1 and fuse them with myeloma cells;

[0017] S3. Use the recombinant protein described in the second aspect to perform positive cloning and subcloning, and screen and obtain a hybridoma cell line that can stably secrete monoclonal antibodies against Clostridium perfringens CPB.

[0018] Furthermore, in step S1, the immunogen is natural CPB.

[0019] Furthermore, the natural CPB refers to the inactivated natural CPB of Clostridium perfringens.

[0020] Furthermore, in step S2, the myeloma cells are SP2 / 0 cells.

[0021] Furthermore, in step S2, the fusion method is a PEG-mediated chemical method.

[0022] Further, in step S3, the positive clone screening refers to the recombinant protein rCPB described in the second aspect. Δ The positive hybridoma cells were screened by indirect ELISA method using coated antigen.

[0023] Furthermore, in step S3, the subclone screening refers to performing a serum neutralization experiment on the cell supernatant of positive hybridoma cells using the prepared natural toxin of Clostridium perfringens, and screening hybridoma cell lines with higher activity after subcloning.

[0024] In a fifth aspect, the present invention provides an anti-clostridium perfringens CPB antibody, wherein the antibody is a monoclonal antibody or a polyclonal antibody; the monoclonal antibody is obtained from the culture fluid of the hybridoma cell line described in the third aspect, or is obtained by inoculating the hybridoma cell line described in the third aspect into the peritoneal cavity of mice to produce ascites; the polyclonal antibody is obtained by immunizing mice with inactivated natural CPB and then using rCPB Δ The protein was inoculated into the peritoneal cavity of mice to produce ascites.

[0025] In a sixth aspect, the present invention provides an antibody blocking ELISA detection method for Clostridium perfringens CPB, wherein the primary antibody is the polyclonal antibody described in the fifth aspect, and the secondary antibody is an HRP-labeled monoclonal antibody.

[0026] Furthermore, the HRP-labeled monoclonal antibody is a monoclonal antibody obtained by purifying the ascites of the monoclonal antibody described in the fifth aspect and then coupling and labeling it with HRP.

[0027] Furthermore, the working dilution of the CPB polyclonal antibody is 1:40, and the working concentration of the monoclonal antibody 1F11 is 1:16000.

[0028] In a seventh aspect, the present invention provides a use of the antibody described in the fifth aspect in preparing a reagent for detecting Clostridium perfringens CPB.

[0029] In an eighth aspect, the present invention provides a kit for detecting Clostridium perfringens CPB, wherein the kit comprises the antibody described in the fifth aspect.

[0030] Furthermore, the kit may be one or more of an ELISA detection kit, a colloidal gold detection kit, an immunohistochemistry kit, an immunofluorescence kit and / or an in situ hybridization staining kit.

[0031] Furthermore, the diagnostic method of the kit includes one or more of a direct method, an indirect method, a double antibody sandwich method and / or a competitive method.

[0032] The hybridoma cell strain secreting anti-CPB monoclonal antibodies in the present invention has been provided with a biological deposit to the General Microbiology Center (CGMCC) of the China Microbiological Culture Collection Administration. The deposit address is the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The name of the deposit is: mouse hybridoma cell, the deposit number is: CGMCCNO.46025, and the deposit date is August 1, 2024.

[0033] Beneficial Effects

[0034] 1. The present invention is the first to obtain a safe, hydrophobic region-truncated CPB recombinant protein rCPB Δ .

[0035] 2. The present invention is the first to use natural CPB as an immune antigen and non-toxic rCPB Δ As coating antigens for screening of monoclonal antibody hybridoma cell lines and the establishment of subsequent ELISA detection methods; the method of using the above two different forms of toxins to screen monoclonal antibody hybridoma cell lines has the following advantages:

[0036] (1) Using a small amount of natural CPB as an immune antigen ensures that the natural conformation of CPB is maintained to the greatest extent;

[0037] (2) Using non-toxic rCPB with a purity of more than 90% Δ Using it as a coating antigen for the screening of positive clones and subclones and the establishment of subsequent ELISA detection methods not only ensures the purity of the coating antigen, but also avoids the cumbersome purification steps and biosafety risks of natural CPB of Clostridium perfringens.

[0038] 3. The present invention is the first to establish an antibody blocking ELISA detection method for CPB using CPB monoclonal antibodies. This method has the characteristics of simple sample operation, low cost, rapid reaction, and strong specificity. It can not only provide a reference for the diagnosis of Clostridium perfringens disease, but also provide a basis for the screening of Clostridium perfringens antibody-negative animals and the study of alternative methods for related vaccine efficacy testing. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 Analysis of the hydrophilicity and hydrophobicity of CPB.

[0040] Figure 2 For rCPB Δ Identification of virulence. DETAILED DESCRIPTION

[0041] The specific embodiments of the present invention are further described below. It should be noted that the description of these embodiments is used to help understand the present invention, but does not constitute a limitation of the present invention. In addition, the technical features involved in the embodiments described below can be combined with each other as long as they do not conflict with each other.

[0042] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0043] Explanation of terms

[0044] Analysis of protein hydrophilicity: Amino acids are the basic units that make up proteases. The amino acid sequence of a protein determines its hydrophilicity, which in turn determines the solubility of the protein in water, thus affecting the conformational stability of the protein in aqueous solution. Generally, in soluble proteases, hydrophilic amino acids are exposed on the outside, while hydrophobic amino acids are folded inside the protein to create a hydrophobic environment suitable for catalytic reactions.

[0045] Hydrophobic amino acids: non-polar amino acids, whose R groups are non-polar, hydrophobic, and not easily soluble in aqueous solutions. Among the 20 standard amino acids that make up proteins, there are 9 hydrophobic amino acids, namely alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), methionine (Met), proline (Pro), tryptophan (Trp), and glycine (Gly). These 9 amino acids are usually located inside the protease molecule, forming a hydrophobic core to maintain the conformational stability of the protease.

[0046] Hydrophilic amino acids: polar amino acids, whose R groups are polar and hydrophilic, can generally form hydrogen bonds with water molecules, so they have a certain affinity for water molecules. Among the 20 standard amino acids that make up proteins, serine (Ser), threonine (Thr), tyrosine (Tyr), cysteine ​​(Cys), asparagine (Asn), glutamine (Gln), aspartic acid (Asp), glutamic acid (Glu), arginine (Arg), lysine (Lys), and histidine (His) are hydrophilic amino acids. In proteins, hydrophilic amino acid residues can form hydrogen bonds and salt bridges with water molecules to maintain the conformational stability of proteins.

[0047] Example 1 Expression and purification of rCPBΔ

[0048] The hydrophilicity and hydrophobicity of CPB of Clostridium perfringens type C (GenBank accession number: AY823400.1) were analyzed using the bioinformatics software DNAStar. Figure 1 As shown, the hydrophilicity is higher in the amino acid region from position 30 to position 306, and its amino acid sequence is shown in SEQ ID NO:1.

[0049] Furthermore, the coding gene of this region was optimized according to the preferred codons of E. coli, and the coding region of the 6×His tag protein was added to the C-terminus of the tandem gene. After codon optimization and synthesis of the gene, the synthetic gene fragment GCPB was finally obtained. Δ GCPB was transformed into Δ Constructed into pET30a vector to obtain the prokaryotic expression vector pET30a-GCPB Δ .

[0050] pET30a-GCPB Δ The vector was transformed into E. coli BL21 (DE3) competent cells for induction expression and purification, and finally the recombinant protein rCPB with a purity of about 90% and a concentration of 0.96 mg / mL was obtained. Δ .

[0051] The toxicity of the protein was tested using ICR mice. Figure 2 As shown, when rCPB Δ When the inoculation dose was 0.1 mg, all mice were alive and had no adverse reactions, while natural CPB of one mouse MLD caused 5 / 5 deaths of mice within 1 hour of inoculation. Δ It is non-toxic in mice and is identified as a non-toxic recombinant fusion protein. The gene was expressed and purified through a prokaryotic expression system to obtain the recombinant protein rCPB Δ .

[0052] Example 2 Preparation of hybridoma cell lines secreting monoclonal antibodies to Clostridium perfringens CPB and preparation of monoclonal antibody ascites

[0053] 1. Immunization of BALB / c mice and determination of antibody titer

[0054] Female BALB / c mice were immunized with inactivated natural CPB as the immunogen by multiple subcutaneous injections. Immunization was performed once every 14 days. Blood was collected from the eye sockets 7 to 10 days after the third immunization. The serum titer was determined by indirect ELISA. If the serum titer reached the fusion requirement (the titer was higher than 12800), booster immunization was performed three days before fusion, and rCPB was directly used. Δ Protein was injected intraperitoneally. 3-5 days after the last immunization, spleen cells from mice with the highest titer were taken for cell fusion.

[0055] 2. Cell fusion and preparation of hybridoma cell lines

[0056] Myeloma cells SP2 / 0 with good growth status were chemically fused with the spleen cells of the mouse with the highest titer detected by ELISA using PEG1450. Δ Positive hybridoma cells were screened by indirect ELISA method of coated antigen, and the cell supernatant of positive hybridoma cells was subjected to serum neutralization experiment with prepared natural toxin of Clostridium perfringens. After 3-5 subclonings by limiting dilution method, a highly active anti-Clostridium perfringens CPB hybridoma cell line was obtained, named 1F11, and the indirect ELISA titer of cell supernatant could reach 1:6400 and above. The subtype was determined to be IgG1 by using subclass identification kit.

[0057] 3. Preparation of ascites with CPB monoclonal antibody

[0058] Select healthy multiparous BALB / c mice aged 6 to 8 months, sensitize them with Freund's incomplete adjuvant intraperitoneally, and inject hybridoma cells 7 days later. Collect the above-mentioned logarithmic growth period hybridoma cells 1F11 and SP2 / 0 cells, centrifuge, wash the cells with DMEM culture medium and resuspend them, and inject hybridoma cells into the mouse peritoneum. When the mouse abdomen is obviously swollen, use a sterile needle to pierce the swollen part of the mouse abdomen to make the ascites flow out or drip out; collect the ascites, centrifuge, mark it as the ascites control (S) of 1F11 and myeloma cells SP2 / 0, and store it at -20℃ for later use.

[0059] Example 3 Purification and detection of monoclonal ascites

[0060] Protein A (GE Healthcare 17-5079-01) affinity column purification method was used for purification, and the purification steps were as follows:

[0061] Sample pretreatment: Ascites was diluted 1:3 with coupling buffer (20 mM sodium phosphate buffer, pH 7.0), and fat, cell residues and small particulate matter were removed after centrifugation.

[0062] Equilibration: Equilibrate the column with 5-10 column volumes of coupling buffer, maintaining a flow rate of 2 s / drop.

[0063] Loading: Inject the sample into the upper interface of the column, collect the effluent, and maintain a flow rate of 4s / drop.

[0064] Washing: Pass 5 column volumes of coupling buffer through the column, maintaining a flow rate of 2s / drop.

[0065] Elution: Elute the antibody with 5 column volumes of elution buffer (0.1 M sodium citrate buffer, pH 9.0), collect, and maintain the flow rate at 4 s / drop.

[0066] Sample detection: The purified monoclonal antibody was identified by SDS-PAGE.

[0067] Conclusion: A monoclonal antibody with a purity of % was obtained by purification using Protein A affinity column; the concentration of the monoclonal antibody was determined by the BCA method, and its concentration could reach 1.8 mg / mL.

[0068] Example 4 HRP labeling of monoclonal antibodies

[0069] Mix the antibody and activated HRP: Take 0.1 mg of antibody, add 25 μL of reagent B, and mix well.

[0070] Add 2 μL of coupling catalyst solution A to the above mixture of antibody and HRP enzyme and mix well.

[0071] Allow to react at room temperature for 2 hours, or overnight at 4°C. The coupled antibody can be used immediately or stored at low temperature.

[0072] Example 5 Establishment of a blocking ELISA detection method for Clostridium perfringens CPB antibody based on monoclonal antibodies 1. Preparation of anti-Clostridium perfringens CPB polyclonal antibodies:

[0073] Using inactivated natural CPB as the immunogen, female BALB / c mice were immunized subcutaneously once every 14 days. 7 to 10 days after the third immunization, an appropriate amount of blood was collected from the eye sockets and the serum titer was determined by indirect ELISA. If the serum titer reached the fusion requirement (titer higher than 12800), blood could be collected.

[0074] 2. Optimal working concentrations of CPB polyclonal antibody standards and monoclonal antibodies

[0075] The purified rCPB was washed with PBS ΔDilute to 2ug / ml, 100μL / well, block overnight at 4℃, wash with PBST, add PBST solution containing 5% skim milk powder as blocking solution, 200μL / well, block at 37℃ for 2h;

[0076] The plate was washed with PBST solution, patted dry, and stored at -20°C for later use.

[0077] Take out the coated ELISA plate, place it at room temperature for 30 minutes, add the obtained anti-Clostridium perfringens CPB polyclonal antibody standard, use PBS as the diluent, and the dilution ratios are original solution, 1:5, 1:10, 1:20, 1:40 and 1:80, 100 μL / well, and add negative serum of corresponding dilution ratio at the same time, and incubate at 37°C for 1 hour.

[0078] Wash with PBST solution, add purified HRP-labeled monoclonal antibody 1F11, use PBS as the diluent, dilute the concentration by 2 times from 1:2000 to 1:64000, 100 μL / well, and incubate at 37°C for 30 min.

[0079] Wash with PBST solution and pat the ELISA plate dry.

[0080] Finally, 50 μL / well of soluble TMB substrate colorimetric solution was added, and the reaction was allowed to proceed for 10 min at room temperature in the dark. The reaction was terminated with 2M H2SO4 solution, and the absorbance was read at 450 nm.

[0081] The OD value of the negative control well is selected to be close to 1.0, and the dilution corresponding to the positive serum blocking rate ≥50% is the optimal working concentration.

[0082] The working dilution of CPB polyclonal antibody was finally determined to be 1:40, and the working concentration of monoclonal antibody 1F11 was 1:16000.

Claims

1. A biological sequence encoding C-type Clostridium perfringens CPB, wherein the biological sequence refers to the 30th to 306th amino acid region with higher hydrophilicity in the CPB sequence of C-type Clostridium perfringens, and the amino acid sequence is shown in SEQ ID NO:

1.

2. A recombinant protein, the recombinant protein is encoded by the biological sequence of claim 1: it is a recombinant protein secreted by the competent cells after the gene fragment encoded by the biological sequence of claim 1 is constructed into a vector and transformed into competent cells, and is named rCPB Δ .

3. A hybridoma cell strain secreting anti-Clostridium perfringens CPB monoclonal antibody, the accession number of the hybridoma cell strain is: CGMCC NO.46025.

4. A method for screening a hybridoma cell line according to claim 3, comprising the following steps: S1. Immunize mice, determine serum titer by ELISA, and use spleen cells of mice with the highest titer for cell fusion; S2. Take the mouse spleen cells screened in S1 and fuse them with myeloma cells; S3. Use the recombinant protein described in claim 2 to perform positive cloning and subcloning, and screen and obtain a hybridoma cell line that can stably secrete monoclonal antibodies against Clostridium perfringens CPB.

5. The method according to claim 4, wherein in step S1, the immunogen is inactivated natural CPB of Clostridium perfringens.

6. The method according to claim 4, wherein in step S3, the positive clone screening is performed using the recombinant protein rCPB according to claim 2 Δ The indirect ELISA method of coated antigen is used to screen positive hybridoma cells; the subclone screening refers to using the prepared natural toxin of Clostridium perfringens to conduct serum neutralization experiments on the cell supernatant of positive hybridoma cells, and screening hybridoma cell lines with higher activity after subcloning.

7. An anti-clostridium perfringens CPB antibody, the antibody being a monoclonal antibody or a polyclonal antibody; the monoclonal antibody being obtained from the culture medium of the hybridoma cell line of claim 3, or being obtained by inoculating the hybridoma cell line of claim 3 into the peritoneal cavity of mice to produce ascites; the polyclonal antibody being obtained by immunizing mice with inactivated natural CPB and then using the recombinant protein rCPB of claim 2 Δ The vaccine is obtained by inoculating into the peritoneal cavity of mice to produce ascites.

8. An antibody blocking ELISA detection method for Clostridium perfringens CPB, wherein the primary antibody is the polyclonal antibody according to claim 7, and the secondary antibody is an HRP-labeled monoclonal antibody; the HRP-labeled monoclonal antibody is a monoclonal antibody obtained by purifying the ascites of the monoclonal antibody according to claim 7 and then coupling and labeling it with HRP; the working dilution of the CPB polyclonal antibody is 1:40, and the working concentration of the monoclonal antibody 1F11 is 1:16000.

9. Use of the antibody according to claim 7 in preparing a reagent for detecting Clostridium perfringens (CPB).

10. A kit for detecting Clostridium perfringens (CPB), comprising the antibody according to claim 7.

Citation Information

Patent Citations

  • Clostridium perfringens

    CN101914145A

  • Antibody capturing ELISA detection method for C.perfringens beta toxin

    CN110261606A

  • Hybridoma cell strain capable of secreting monoclonal antibody neutralizing clostridium septicum alpha toxin and application thereof

    CN111484983A

Cited By

  • Clostridium perfringens ETX hybridoma cell strain and application thereof

    CN119979480A

  • Specific binding protein of clostridium perfringens delta toxin, nucleic acid molecule, carrier, cell as well as preparation method and application of specific binding protein

    CN122444865A